×
Log In Create an Account
  • Home
  • About ECOS
  • Events
    • ECOS 2021
    • ECOS 2019
    • Cardio-oncology Calendar
  • Online Courses
    • Essentials of Cardio-oncology
    • Webcasts
    • IO Primers
  • Contact
 Sections
  • Imaging guidelines in cardio-oncology
  • Revolutionising cancer care with immunotherapy
  • Cardiac complications of checkpoint inhibitor therapy
  • Cardiac complications of checkpoint inhibitor therapy

    Saturday 19 October 2019
    9:30 - 10:30 CEST | 15:30 - 16:30 Beijing

     

    Sign up here to be notified when this webcast is available online for viewing and CME credit.


    Chair

    Jeroen Bax, MD, PhD
    Leiden University Medical Center
    Leiden, The Netherlands

    Javid Moslehi, MD
    Vanderbilt University Medical Center
    Nashville, TN, USA

     

    Faculty

    Shanthini Crusz, MD
    Barts Health NHS Trust
    London, UK

    Joe-elie Salem, MD, PhD
    Sorbonne Université, AP-HP
    Paris, France

    Jecko Thachil, MD, FRCPath
    Manchester Royal Infirmary
    Manchester, UK


    Overview

    In this multidisciplinary webcast, global experts in cardiology and oncology will discuss the practical implications of new data on the cardiotoxicity of checkpoint inhibitors, using real-world cases to illustrate clinical pearls for the cardio-oncology service.


    Learning objectives

    Upon completion of this activity, participants will be better able to:

    • Recognise the unique cardiotoxicity profile of immune checkpoint inhibitors
    • Apply evidence-based strategies to the diagnosis and management of cardiotoxicity during and after treatment with checkpoint inhibitors

     
    Registration

    Registration is now closed.

    Target audience

    This activity is primarily intended for clinicians who have special interest in the cardiovascular needs of patients with cancer, including cardiologists, oncologists, nurses, and other members of the multidisciplinary cardio-oncology team. 

     

    Financial disclosures

    Shanthini Crusz
    Educational Travel Grant: Tesaro.

    Javid Moslehi
    Consultancy: Acceleron, Ariad, BMS, Daiichi-Sankyo, Deciphera, Heat Biologics, Incyte, Ipsen, Myokardia, Novartis, Pharmacyclics, Pfizer, Regeneron, Redux Therapeutics, Rgenix, StemCentRx, Takeda/Millennium, Vertex, Verastem.
    Research grants: BMS, Pfizer.
    Shares: Redux Therapeutics.

    Jecko Thachil
    Speaker’s Bureau: Bayer, Boehringer-Ingelheim, Daichii-Sankyo, Pfizer.

    Jeroen Bax and Joe-elie Salem have no relevant financial relationships to disclose.

    Staff at Siyemi Learning have no relevant financial relationships to disclose.

     

    Continuing medical education

    Siyemi Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Siyemi Learning designates this live activity for 1 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

     

    Commercial support

    The ECOS 2019 meeting was supported by an independent medical educational grant from Novartis and in-kind support for the pre-conference workshop was provided by GE Healthcare.

     

    How to earn your CME credit

    At the end of the live webcast you will be required to complete a short post-test, you will then be directed to the ECOS website where you will be able to complete the evaluation and download your CME certificate.

    Please contact us at cme@cme-cpd.org with any questions or concerns.

    Sign up here to be notified when this webcast is available online for viewing and CME credit.

  •  

     

 
Follow Us
 
 
 

The University of Manchester Innovation Centre (UMIC)

Arch 29, North Campus Incubator
Sackville Street
Manchester M60 1QD
United Kingdom
+44 161 408 6084 
 info@cme-cpd.org
Privacy statement | Terms and conditions. Unless explicitly stated, all material © 2018 CME-CPD Academy
CME-CPD Academy is a division of Siyemi Limited, incorporated in England and Wales, 5883995.